Summary

In this report, our team research the global Antisense and RNAi Therapeutics market by type, application, region and manufacturer 2014-2020 and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Antisense and RNAi Therapeutics for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America

Global Antisense and RNAi Therapeutics market competition by top manufacturers/players, with Antisense and RNAi Therapeutics sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
Glaxo Smith Kline
Sanofi Aventis / Genzyme
Isis Pharmaceuticals/ Ionis Pharmaceuticals
Arbutus Biopharma Ltd.
Silence Therapeutics
Bio-Path Holdings Inc.
Calando Pharmaceuticals
ICo Therapeutics
Quark Pharmaceuticals
Rexhan Pharmaceuticals
Biomarin/Prosensa
Regulus Therapeutics
Rxi Pharmaceuticals
Silenseed
Dicerna Pharmaceuticals
Sirnaomics Inc
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
RNA interference
SiRNA
MiRNA
Antisense RNA
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Antisense and RNAi Therapeutics for each application, including
Oncology
Cardiovascular
Renal
Neurodegenerative
Respiratory
Genetic
Infectious Diseases

If you have any special requirements, please let us know and we will offer you the report as you want.

1 Executive Summary
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Antisense and RNAi Therapeutics Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Analysis by Types
2.1 Overall Market Performance(Volume)
2.1.1 RNA interference
2.1.2 SiRNA
2.1.3 MiRNA
2.1.4 Antisense RNA
2.2 Overall Market Performance(Value)
2.2.1 RNA interference
2.2.2 SiRNA
2.2.3 MiRNA
2.2.4 Antisense RNA
3 Product Application Market
3.1 Overall Market Performance (Volume)
3.1.1 Oncology
3.1.2 Cardiovascular
3.1.3 Renal
3.1.4 Neurodegenerative
3.1.5 Respiratory
3.1.6 Genetic
3.1.7 Infectious Diseases
4 Manufacturers Profiles/Analysis
4.1 Glaxo Smith Kline
4.1.1 Glaxo Smith Kline Profiles
4.1.2 Glaxo Smith Kline Product Information
4.1.3 Glaxo Smith Kline Antisense and RNAi Therapeutics Sales, Sales Value(Million USD), Price and Gross Profit
4.1.4 Glaxo Smith Kline SWOT Analysis
4.2 Sanofi Aventis / Genzyme
4.2.1 Sanofi Aventis / Genzyme Profiles
4.2.2 Sanofi Aventis / Genzyme Product Information
4.2.3 Sanofi Aventis / Genzyme Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.2.4 Sanofi Aventis / Genzyme SWOT Analysis
4.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals
4.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Profiles
4.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Product Information
4.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals SWOT Analysis
4.4 Arbutus Biopharma Ltd.
4.4.1 Arbutus Biopharma Ltd. Profiles
4.4.2 Arbutus Biopharma Ltd. Product Information
4.4.3 Arbutus Biopharma Ltd. Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.4.4 Arbutus Biopharma Ltd. SWOT Analysis
4.5 Silence Therapeutics
4.5.1 Silence Therapeutics Profiles
4.5.2 Silence Therapeutics Product Information
4.5.3 Silence Therapeutics Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.5.4 Silence Therapeutics SWOT Analysis
4.6 Bio-Path Holdings Inc.
4.6.1 Bio-Path Holdings Inc. Profiles
4.6.2 Bio-Path Holdings Inc. Product Information
4.6.3 Bio-Path Holdings Inc. Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.6.4 Bio-Path Holdings Inc. SWOT Analysis
4.7 Calando Pharmaceuticals
4.7.1 Calando Pharmaceuticals Profiles
4.7.2 Calando Pharmaceuticals Product Information
4.7.3 Calando Pharmaceuticals Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.7.4 Calando Pharmaceuticals SWOT Analysis
4.8 ICo Therapeutics
4.8.1 ICo Therapeutics Profiles
4.8.2 ICo Therapeutics Product Information
4.8.3 ICo Therapeutics Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.8.4 ICo Therapeutics SWOT Analysis
4.9 Quark Pharmaceuticals
4.9.1 Quark Pharmaceuticals Profiles
4.9.2 Quark Pharmaceuticals Product Information
4.9.3 Quark Pharmaceuticals Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.9.4 Quark Pharmaceuticals SWOT Analysis
4.10 Rexhan Pharmaceuticals
4.10.1 Rexhan Pharmaceuticals Profiles
4.10.2 Rexhan Pharmaceuticals Product Information
4.10.3 Rexhan Pharmaceuticals Antisense and RNAi TherapeuticsSales, Sales Value (Million USD), Price and Gross Profit
4.10.4 Rexhan Pharmaceuticals SWOT Analysis
4.11 Biomarin/Prosensa
4.12 Regulus Therapeutics
4.13 Rxi Pharmaceuticals
4.14 Silenseed
4.15 Dicerna Pharmaceuticals
4.16 Sirnaomics Inc
5 Market Performance for Manufacturers
5.1 Global Antisense and RNAi Therapeutics Sales (K Units) and Market Share by Manufacturers 2014-2020
5.2 Global Antisense and RNAi Therapeutics Revenue (M USD) and Market Share by Manufacturers 2014-2020
5.3 Global Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
5.4 Global Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
5.5 Market Concentration
6 Regions Market Performance for Manufacturers
6.1 China Market Performance for Manufacturers
6.1.1 China Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.1.2 China Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.1.3 China Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.1.4 China Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.1.5 Market Concentration
6.2 USA Market Performance for Manufacturers
6.2.1 USA Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.2.2 USA Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.2.3 USA Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.2.4 USA Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.2.5 Market Concentration
6.3 Europe Market Performance for Manufacturers
6.3.1 Europe Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.3.2 Europe Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.3.3 Europe Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.3.4 Europe Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.3.5 Market Concentration
6.4 Japan Market Performance for Manufacturers
6.4.1 Japan Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.4.2 Japan Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.4.3 Japan Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.4.4 Japan Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.4.5 Market Concentration
6.5 Korea Market Performance for Manufacturers
6.5.1 Korea Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.5.2 Korea Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.5.3 Korea Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.5.4 Korea Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.5.5 Market Concentration
6.6 India Market Performance for Manufacturers
6.6.1 India Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.6.2 India Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.6.3 India Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.6.4 India Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.6.5 Market Concentration
6.7 Southeast Asia Market Performance for Manufacturers
6.7.1 Southeast Asia Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.7.2 Southeast Asia Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.7.3 Southeast Asia Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.7.4 Southeast Asia Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.7.5 Market Concentration
6.8 South America Market Performance for Manufacturers
6.8.1 South America Antisense and RNAi Therapeutics Sales (K Units) and Share of Manufacturers 2014-2020
6.8.2 South America Antisense and RNAi Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2020
6.8.3 South America Antisense and RNAi Therapeutics Price (USD/Unit) of Manufacturers 2014-2020
6.8.4 South America Antisense and RNAi Therapeutics Gross Margin of Manufacturers 2014-2020
6.8.5 Market Concentration
7 Global Antisense and RNAi Therapeutics Market Assessment by Regions (2014-2020)
7.1 Global Antisense and RNAi Therapeutics Sales (K Units) and Market Share by Regions 2014-2020
7.2 Global Antisense and RNAi Therapeutics Revenue (M USD) and Market Share by Regions 2014-2020
7.3 Global Antisense and RNAi Therapeutics Price (USD/Unit) by Regions 2014-2020
7.4 Global Antisense and RNAi Therapeutics Gross Margin by Regions 2014-2020
8 Development Trend for Regions
8.1 Global Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.2 China Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.3 USA Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate2014-2020
8.4 Europe Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.5 Japan Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.6 Korea Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.7 India Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.8 Southeast Asia Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
8.8 Southeast Asia Antisense and RNAi Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2020
9 Upstream Source, Technology and Cost
9.1 Upstream Source
9.2 Technology
9.3 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Manufacturing Plants Distribution
11 Consumer Analysis
11.1 Oncology Industry
11.2 Cardiovascular Industry
11.3 Renal Industry
11.4 Neurodegenerative Industry
11.5 Respiratory Industry
11.6 Genetic Industry
11.7 Infectious Diseases Industry
12 Market Forecast 2021-2026
12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
12.1.1 Global Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
12.1.2 Global Antisense and RNAi Therapeutics Sales (K Units) and Growth Rate 2021-2026
12.1.3 China Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.4 USA Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.5 Europe Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.6 Japan Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.7 Korea Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.8 India Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.9 Southeast Asia Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.10 South America Antisense and RNAi Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2021-2026
12.2.1 Overall Market Performance
12.2.2 RNA interference
12.2.3 SiRNA
12.2.4 MiRNA
12.2.5 Antisense RNA
12.3 Sales (K Units) Forecast by Application 2021-2026
12.3.1 Overall Market Performance
12.3.2 Oncology
12.3.3 Cardiovascular
12.3.4 Renal
12.3.5 Neurodegenerative
12.3.6 Respiratory
12.3.7 Genetic
12.3.8 Infectious Diseases
12.4 Price (USD/Unit) and Gross Profit
12.4.1 Global Antisense and RNAi Therapeutics Price (USD/Unit) Trend 2021-2026
12.4.2 Global Antisense and RNAi Therapeutics Gross Profit Trend 2021-2026
13 Conclusion